Five values for COVID-19 vaccine acceptance described by racial and ethnic minoritized caregivers [0.03%]
五种COVID-19疫苗接受度价值观，按被边缘化的少数种族和民族的照料者的分类描述
Sonal Jain,Rohan Dayal,Jennifer Sikov et al.
Sonal Jain et al.
Background and objectives: Persistent racial and ethnic disparities in child COVID-19 vaccination rates in the US suggest that vaccinated racial and ethnic minoritized caregivers have hesitated to vaccinate their children...
Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients [0.03%]
癌症患者接种新冠疫苗后对SARS-CoV-2变异株的中和抗体反应（由MSD多重检测评估）
Christopher W Dukes,Junmin Whiting,Qianxing Mo et al.
Christopher W Dukes et al.
Background: Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 v...
Cross-country analysis on HPV vaccination behaviors among health workers and parents: a qualitative report from seven middle-income countries [0.03%]
七个人均收入国家HPV疫苗接种行为的跨国分析：定性研究报告
Gulaiim Almatkyzy,Sahil Khan Warsi,Siff Malue Nielsen et al.
Gulaiim Almatkyzy et al.
Purpose: This article presents a cross-country analysis of qualitative research reports on the barriers and drivers of HPV vaccination-related behavior among parents and health workers in seven middle-income countries usi...
Estimating historical impacts of vaccination against influenza B/Yamagata in the United States to inform possible risks of re-emergence in the absence of vaccination [0.03%]
估计美国针对乙型山形流感病毒的疫苗往绩影响，以评估在缺乏该疫苗的情况下可能出现的风险
Sinead E Morris,Sarabeth M Mathis,Jessie R Chung et al.
Sinead E Morris et al.
Influenza B/Yamagata viruses have not been detected globally since 2020 and were removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17-2019/20 by combining B/Yamagata preva...
Estimating historical disease burden and the impact of vaccination by influenza type and subtype in the United States, 2016-2020 [0.03%]
2016—2020年美国各类各型流感疾病负担估计及疫苗效果评价
Sinead E Morris,Sarabeth M Mathis,Jessie R Chung et al.
Sinead E Morris et al.
Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease burden and burden prevented by vacci...
High HBV Seroprotection Rates in Infants Born to People with HIV and HBV Infection in Sub-Saharan Africa [0.03%]
东非艾滋病和乙肝病毒携带者所生婴儿的高乙肝表面抗体阳性率
Neaka Mohtashemi,Julia Spaczai,Rong Guo et al.
Neaka Mohtashemi et al.
Rhamnose polysaccharide-decorated outer membrane vesicles as a vaccine candidate targeting Group A Streptococcus from Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis [0.03%]
来自化脓链球菌和嗜马产诱导菌的A群链球菌包被鼠李糖多糖外膜囊泡疫苗候选者
Sowmya Ajay Castro,Sarah Thomson,Helen Alexandra Shaw et al.
Sowmya Ajay Castro et al.
Group A Streptococcus (Strep A) cause a wide range of human-exclusive infections, annually killing more than 500,000 people. Antibiotic resistance incidence of invasive Strep A tripled in the past decade and emphasises the need to develop a...
Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV [0.03%]
RSV预防性临床试验多重终点设置研讨会
O Prunas,J Willemsen,J L Warren et al.
O Prunas et al.
A meeting held in Lisbon, Portugal, in February 2023 focused on critical aspects of clinical trial design for respiratory syncytial virus (RSV) preventative therapies. The meeting addressed two primary areas: enhancing the efficiency and su...
Corrigendum to "Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review". [Vaccine X, 2024 Feb 23;18:100464] [0.03%]
关于“比较母体疫苗研究中特殊关注不良事件的定义和报告：系统评价”的勘误表[Vaccine X，2024年2月23日；18(100464)]
Hannah G Davies,Emma V Thorley,Rossul Al-Bahadili et al.
Hannah G Davies et al.
[This corrects the article DOI: 10.1016/j.jvacx.2024.100464.]. © 2025 The Author(s).
Published Erratum
Vaccine: X. 2025 Feb 5:23:100612. DOI:10.1016/j.jvacx.2025.100612 2025
Costs estimation of three models of COVID-19 vaccination in Beijing, China [0.03%]
在中国北京三种新冠疫苗接种方案的成本估算
Hongzeng Wang,Dan Zhao,Xiaomei Li et al.
Hongzeng Wang et al.
Since the emergency use authorization for the COVID-19 vaccine in 2021, the Chinese government has used three vaccination models: vaccination clinic, mass vaccination center, and door-to-door service. This study compared these three differe...